ProQR Q2 revenue more than doubles

ProQR Therapeutics NV

13/08/2026 12:11

Overview
Netherlands-based RNA therapy developer's Q2 revenue more than doubled, beating analyst expectations
Company's net loss narrowed from a year earlier
ProQR raised €59.2 mln in financing, ending Q2 with €117.1 mln cash

Outlook
ProQR expects full Phase 1 AX-0810 dataset presentation at a scientific conference later in 2026
Company anticipates initial AX-0811 Phase 1 data by year-end 2026, pending regulatory authorization
Initial clinical data from biliary atresia and other pipeline programs expected in H1 2027

Result Drivers
FINANCING BOOST - €59.2 mln raised in Q2 to support continued advancement of Axiomer pipeline and clinical milestones

Company press release: ID:nGNEmGrlQ

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
EUR 8.76 mln
EUR 4.58 mln (5 Analysts)
Q2 Loss Per Share
 
EUR 0.08
 
Q2 Net Loss
 
EUR 8.73 mln
 
Q2 Loss Per Basic Share
 
EUR 0.08
 
Q2 Operating Income
 
-EUR 8.82 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for ProQR Therapeutics NV is $9.00, about 383.9% above its August 12 closing price of $1.86

Reuters Recommended Reads
Aug 12 - Arbutus Biopharma swings to Q2 loss as revenue falls; plans up to $230 mln shareholder returns
Aug 12 - Switzerland's Pharvaris Q2 loss narrows, cash rises to €318 mln
Aug 13 - Denmark's Zealand Pharma H1 revenue, profit fall sharply

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)